Potential Conflict of Interest In Federal Health Agency

Last November, the Department of Health and Human Services removed “black box” warnings on hormone replacement therapies. This decision sought to decrease the stigma around treatments for menopause symptoms. Alicia Jackson, director of a federal health agency, praised the decision at a press conference. She described it as a win for women and science, emphasizing the treatment’s safety and benefits.

Alicia Jackson previously founded Evernow, a platform that links women with menopause experts. Although she entered federal service, she retained a significant amount of Evernow stock. This situation underscores potential conflicts of interest as she managed the Advanced Research Projects Agency for Health (ARPA-H).

The Food and Drug Administration, responsible for drug regulation, recommended ending the warning months before Jackson’s government role. However, ethics experts raised concerns about Jackson’s involvement, citing federal laws prohibiting participation in matters affecting personal finances.

Virginia Canter, an ethics lawyer with governmental experience, highlighted the conflict of interest. Jackson remained in possession of Evernow stock and options, a situation complicated by her husband’s venture capital portfolio, raising questions about her impartiality in her official role.

Despite ethics compliance necessitating financial disclosure, Jackson’s submissions remain uncertified. Canter pointed out that ethics offices sometimes request inspector general investigations for uncertain disclosure forms.

ProPublica sought Jackson’s responses regarding her work and financial interests, without reply. An HHS spokesperson later confirmed Jackson’s administrative leave, citing pending fact assessments to decide her position. Queries concerning the reasons behind Jackson’s leave or inspector general investigations remain unanswered.

A report from Bloomberg Law disclosed a draft memo for Jackson’s potential conflict waiver, permitting involvement in specific financial interest decisions. Her broad investment holdings include companies benefiting from ARPA-H, causing procedural and ethical scrutiny.

Federal employees must disclose spousal employment, yet Jackson neglected to mention her husband’s role at 137 Ventures in public records. Ethics experts concerned about conflicts note that Jackson must identify fund holdings, possibly necessitating asset sales to maintain ethical compliance.

Jackson’s disclosures reveal investment growth in Gameto Inc., a company receiving substantial ARPA-H funding. Her financial interests, including varied venture and equity funds, potentially conflict with her duties unless appropriately disclosed and managed.

Palantir Technologies, linked to her husband’s investments, benefited from ARPA-H contracts. Though allowed to partake in related decisions by a proposed waiver, oversight and compliance with ethics agreements remain uncertain.

Ethics concerns extend beyond Jackson. Health Secretary Robert F. Kennedy Jr. faced scrutiny over potential conflicts relating to his wife’s company profits from his endorsed initiatives. Disclosures indicate gifts and financial interests challenging HHS’ ethical standards.

Issues of non-compliance persist, further complicated by workforce reductions affecting ethics oversight capabilities. Transparency and accountability remain crucial in maintaining public trust amidst ethical dilemmas and financial disclosures.